key: cord-0796877-221kdgdb authors: Dassarma, Barsha; Tripathy, Satyajit; Matsabisa, Motlalepula title: Emergence of Ancient Convalescent plasma (CP) Therapy: to Manage COVID-19 Pandemic date: 2020-12-05 journal: Transfus Clin Biol DOI: 10.1016/j.tracli.2020.11.004 sha: 367971a0d69da04641a58b2a4f65e217ae73f3c3 doc_id: 796877 cord_uid: 221kdgdb Since December 2019, the human populations of the 195 global countries continue experiencing grave health and life threats due to the current COVID-19 pandemic. As a result of the novelty of the pathogen, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), at present there is lack of preventive as well as therapeutic options for treating and managing the infection. The use of ancient immunotherapeutic technique – the Convalescent plasma (CP) therapy, may act as an immediate and available option to control the COVID-19 pandemic. This review provides a concept and understanding on the CP therapy, its potential to control SARS-CoV-2 pandemic. The CP therapy might act as an immediate saviour for society from the virus. Although the CP therapy has exert affirmative result against COVID-19 it has not been recommended for long time use in COVID-19 and this review gives support for its possible application. In December 2019, an infectious type of pneumonia associated with severe acute respiratory Currently there's no approved effective vaccine or medication for COVID-19, although 76 the disease spreading like wildfire globally. There is the greatest necessity to find alternative 77 therapeutic strategies for COVID -19. There is certain old treatment, like the convalescent plasma 78 (CP) treatment that could provide some relief for the disease. The classic adaptive immunotherapy, 79 convalescent plasma (CP) therapy is one option that could be considered in the management of 80 COVID-19 disease based on clinical trial evidences collected (Table 1) . One key possible 81 determinant is that CP therapy is dependent on those people who recovered from the infection to 82 donate their immunoglobulin-containing serum which is to be used in the treatment regimen. Hark back: 271 passive immunotherapy for influenza and other serious infections. Critical care medicine Meta-analysis: convalescent blood products 274 for Spanish influenza pneumonia: a future H5N1 treatment? Convalescent plasma treatment reduced mortality in patients with severe pandemic 278 influenza A (H1N1) 2009 virus infection Treatment with convalescent plasma for influenza A (H5N1) 281 infection Successful treatment of avian-origin 283 influenza A (H7N9) infection using convalescent plasma. International Journal of Infectious 284 Diseases Evaluation of convalescent whole blood for treating Ebola 287 Journal of Infection Evaluation of convalescent plasma for 290 Ebola virus disease in Guinea Experience of using convalescent plasma for severe acute respiratory syndrome 300 among healthcare workers in a Taiwan hospital The 307 feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. 308 medRxiv Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Hyperimmune globulins and same-day thrombotic adverse 317 events as recorded in a large healthcare database during 2008-2011. American journal of 318 hematology Treatment of COVID-19: old tricks for new 320 challenges Antibody-dependent enhancement of virus infection and disease. Viral 322 immunology Medical countermeasures analysis of 2019-nCoV and vaccine risks for 324 antibody-dependent enhancement (ADE)